Twitter and Diabetes

Diabetes Clinical Trial

Official title:

Twitter and Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02806700
• Other study ID #: R01: HL122457-0IA1
• Status: Completed
• Phase: N/A
• Start date: June 2016
• Est. completion date: August 2018

Study information

• Verified date: April 2018
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Twitter use is surprisingly well represented across broad demographic population segments and health-related messages. The promise of using Twitter is that its use is growing rapidly, it allows the investigators to view communications that were impossible to intercept before, and it potentially provides information faster and less expensively than collection from other media channels. Prior work also supports that social media interventions can improve health behavior change (e.g. weight loss, physical activity) and outcomes.The overarching goals of this proposal are to understand the uses and limitations of this communication channel to improve patients' ability to manage their CV health condition.

Description:

Use Twitter to deliver high impact CV health related content to improve patient activation and disease management for diabetes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: August 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• diabetes

• uses social media

Exclusion Criteria:

• <21 years of age

• pregnant

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Diabetes
• Diabetes Mellitus

Intervention

Behavioral:
• Twitter Diabetes Intervention
This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient Activation	PAM scale with an anticipated 2-3 point difference	6 months
Secondary	HbA1c	self reported HbA1c	6-12 months